Boston Scientific Corporation $BSX Stock: Ninety One UK Ltd Lowers Holdings

Ninety One UK Ltd lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 99.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,658 shares of the medical equipment provider’s stock after selling 3,484,327 shares during the period. Ninety One UK Ltd’s holdings in Boston Scientific were worth $771,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. State of Alaska Department of Revenue grew its stake in Boston Scientific by 11.8% in the 3rd quarter. State of Alaska Department of Revenue now owns 162,750 shares of the medical equipment provider’s stock valued at $7,104,000 after buying an additional 17,115 shares during the last quarter. Chiron Capital Management LLC raised its holdings in Boston Scientific by 8.4% in the 3rd quarter. Chiron Capital Management LLC now owns 20,601 shares of the medical equipment provider’s stock worth $899,000 after acquiring an additional 1,600 shares during the period. WealthPlan Investment Management LLC bought a new position in Boston Scientific in the 3rd quarter worth $203,000. Mainsail Asset Management LLC bought a new position in Boston Scientific in the 3rd quarter worth $234,000. Finally, Nvwm LLC lifted its position in Boston Scientific by 526.2% during the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 542 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

NYSE:BSX opened at $44.17 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a one year low of $41.38 and a one year high of $105.65. The company has a fifty day moving average price of $46.16 and a 200 day moving average price of $49.80. The stock has a market cap of $64.02 billion, a P/E ratio of 17.88, a PEG ratio of 1.04 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts anticipate that Boston Scientific Corporation will post 3.24 earnings per share for the current year.

Insider Activity

In related news, Director David Habiger bought 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward Ludwig bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on BSX. Evercore decreased their price target on shares of Boston Scientific from $65.00 to $52.00 and set an “outperform” rating for the company in a report on Wednesday, October 7th. Mizuho set a $55.00 price target on Boston Scientific in a research report on Tuesday. Royal Bank Of Canada dropped their price objective on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, July 30th. Truist Financial cut their price objective on Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 target price (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $68.23.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.